Business Context and Reporting Period
Company: Quantum-Si Inc (QSI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Quantum-Si is an early-stage life sciences company developing Next-Generation Protein Sequencing (NGPS) tools. The company commercializes the Platinum and Platinum Pro instruments, consumable kits, and analysis software for proteomics research. The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3,058 | $1,082 |
| Cost of Revenue | $1,458 | $594 |
| Gross Profit | $1,600 | $488 |
| Gross Margin | 52.3% | 45.1% |
| Net Loss | $(101,007) | $(95,960) |
| Operating Cash Flow | $(87,795) | $(94,036) |
| Cash & Marketable Securities (Dec 31, 2024) | $209,603 | $257,736 |
| Accumulated Deficit | $(596,641) | $(495,634) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 182.6% to $3.1 million, driven by the full commercial launch of the Platinum instrument in Q2 2024. Product revenue grew 183.7% and service revenue grew 160.8%.
- Net Loss Expansion: Net loss increased 5.3% to $101.0 million. This was primarily due to a $3.7 million loss from the change in fair value of warrant liabilities and increased selling, general, and administrative (SG&A) expenses.
- Expense Management: Research and Development (R&D) expenses decreased 11.0% to $59.6 million due to restructuring activities and capitalization of personnel costs. Conversely, SG&A expenses increased 13.2% to $50.5 million due to investments in commercial operations and legal fees.
- Investment Income: Dividend and interest income increased 19.2% to $11.4 million due to higher market interest rates on invested balances.
- Warrant Liability: The change in fair value of warrant liabilities resulted in a $3.7 million loss in 2024, compared to a $0.3 million loss in 2023, driven by fluctuations in the underlying stock price.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Product Roadmap: The company launched Platinum Pro in January 2025 with shipments expected by Q1 2025. The next-generation "Proteus" platform is targeted for launch in H2 2026, aiming to significantly scale sequencing output.
- Commercialization: The company entered a distribution agreement with Avantor for North America in late 2024. It maintains 18 international distribution partners.
- Liquidity: Management believes existing cash and marketable securities ($209.6 million as of Dec 31, 2024) are sufficient to fund operations for at least the next 12 months.
Recent Capital Raises:
- ATM Offering: Sold 23.4 million shares in 2024 for net proceeds of $34.8 million.
- Registered Direct Offering: On January 3, 2025, sold 15.6 million shares for gross proceeds of $50.0 million (net proceeds approx. $46.9 million).
Key Risks and Contingencies:
- Profitability: The company has a history of net losses and negative cash flow, with no assurance it will achieve profitability.
- Supply Chain: Reliance on third-party foundries for silicon wafers and contract manufacturers for instruments. Transitioning semiconductor chip manufacturing processes is ongoing and carries execution risk.
- Regulatory: Products are currently "Research Use Only" (RUO). Future clinical applications would require FDA clearance/approval, which is costly and uncertain.
- Legal Proceedings: Pending litigation includes a stockholder lawsuit regarding the 2021 business combination and a dispute with a former contract manufacturer. Outcomes are not estimable.
- Internal Controls: The company previously experienced material weaknesses in internal controls (related to warrant accounting and outsourced finance functions) but concluded controls were effective as of Dec 31, 2024.
Investor Verification Checklist
- Runway Validation: Verify if the $209.6 million cash balance (plus the $46.9 million Jan 2025 raise) is sufficient given the $101M annual burn rate and potential acceleration of commercialization spend.
- Revenue Quality: Assess the mix of instrument sales vs. recurring consumable revenue to gauge the sustainability of the 182% revenue growth.
- Manufacturing Transition: Monitor the status of the semiconductor chip surface coating process transition to the new contract manufacturer, as delays could impact consumable supply.
- Warrant Liability Impact: Review the sensitivity of the $5.0 million warrant liability to stock price volatility, as this creates non-cash earnings volatility.
- Legal Exposure: Track the status of the Delaware Stockholder Litigation and the contract manufacturer dispute for potential financial impact.